CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Sees Significant Increase in Short Interest

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totaling 3,450,760 shares, an increase of 136.4% from the September 30th total of 1,459,951 shares. Currently, 7.0% of the company’s stock are short sold. Based on an average daily trading volume, of 342,939 shares, the short-interest ratio is currently 10.1 days.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Zacks Research raised CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of CAMP4 Therapeutics in a report on Tuesday, September 29th. Raymond James Financial initiated coverage on shares of CAMP4 Therapeutics in a research report on Friday, October 23rd. They set a “strong-buy” rating and a $10.00 price target for the company. Wall Street Zen cut shares of CAMP4 Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 10th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.44.

Insider Buying and Selling at CAMP4 Therapeutics

In other CAMP4 Therapeutics news, Director Richard Young purchased 16,378 shares of CAMP4 Therapeutics stock in a transaction dated Monday, August 3rd. The stock was acquired at an average price of $1.65 per share, for a total transaction of $27,023.70. Following the acquisition, the director owned 186,388 shares in the company, valued at $307,540.20. This trade represents a 9.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kelly Gold acquired 10,000 shares of CAMP4 Therapeutics stock in a transaction that occurred on Monday, August 31st. The stock was acquired at an average cost of $3.96 per share, with a total value of $39,600.00. Following the purchase, the chief financial officer directly owned 10,000 shares of the company’s stock, valued at $39,600. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have acquired 46,031 shares of company stock valued at $99,051 and have sold 593,613 shares valued at $2,504,037. Insiders own 21.69% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CAMP. Jupiter Topco LLC acquired a new position in CAMP4 Therapeutics in the 2nd quarter valued at $27,581,000. 5AM Venture Management LLC acquired a new stake in CAMP4 Therapeutics during the 2nd quarter worth $25,647,928. Trails Edge Capital Partners LP acquired a new stake in CAMP4 Therapeutics during the 2nd quarter worth $8,446,935. BlackRock Inc. purchased a new stake in CAMP4 Therapeutics during the 2nd quarter valued at about $7,185,000. Finally, SummitTX Capital L.P. purchased a new stake in shares of CAMP4 Therapeutics in the first quarter valued at approximately $1,497,000.

CAMP4 Therapeutics Price Performance

CAMP stock traded down $0.10 during mid-day trading on Friday, reaching $3.81. 19,894 shares of the company’s stock were exchanged, compared to its average volume of 202,625. The stock’s 50 day moving average is $3.90 and its 200 day moving average is $4.25. CAMP4 Therapeutics has a 12-month low of $2.90 and a 12-month high of $7.75. The company has a market cap of $238.76 million, a price-to-earnings ratio of -1.64 and a beta of 0.27.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.34). The company had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. On average, research analysts forecast that CAMP4 Therapeutics will post -0.68 earnings per share for the current fiscal year.

About CAMP4 Therapeutics

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company’s approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit.

CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes.